ANI PHARMACEUTICALS INC (ANIP)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Net revenues | 211,371 | 148,332 | 138,040 | |
| Selling, general, and administrative | 81,771 | 79,075 | 52,821 | |
| Research and development | 16,535 | 10,128 | 7,296 | |
| Gain on sale of building | - | - | - | |
| Depreciation and amortization | 23,281 | 15,748 | 14,697 | |
| Cost of sales (excluding depreciation and amortization) | 74,615 | 63,075 | 57,698 | |
| Contingent consideration fair value adjustment | 1,277 | 825 | 359 | |
| Total operating expenses, net | 197,479 | 168,851 | 132,871 | |
| Operating income | 13,892 | -20,519 | 5,169 | |
| Interest expense, net | -5,438 | -2,331 | -4,656 | |
| Unrealized gain (loss) on investment in equity securities | 332 | 1,355 | -2,712 | |
| Other income (expense), net | 1,739 | -2,535 | -88 | |
| Loss on extinguishment of debt | - | -7,468 | - | |
| Income (loss) before income tax expense | 10,525 | -31,498 | -2,287 | |
| Income tax expense | 1,976 | -7,332 | - | |
| Net income (loss) | 8,549 | -24,166 | -2,287 | |
| Dividends on series a convertible preferred stock | 407 | 406 | 407 | |
| Net income (loss) available to common shareholders | 8,142 | -24,572 | -2,694 | |
| Basic income (loss) per share(in dollars per share) | 0.37 | -1.27 | -0.14 | |
| Basic weighted-average shares outstanding (in shares) | 19,834,000 | 19,404,000 | 19,321,000 | |
| Diluted income (loss) per share (in dollars per share) | 0.36 | -1.27 | -0.14 | |
| Diluted weighted-average shares outstanding (in shares) | 20,308,000 | 19,404,000 | 19,321,000 | |